BioPharmSignal logoBioPharmSignal

Biotech News

iBio Received Regulatory Clearance to Initiate Its Phase 1 Clinical Trial of IBIO-600 in Australia

Ibio Inc (IBIO)Ibio IncClinical readout

IBIO (IBIO) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is ibio.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Related news

IBIOIbio Inc2026-06-02 11:00 EST

iBio Becomes a Clinical-Stage Company with First Participant Dosed in Phase 1 Clinical Trial of IBIO-600 in Adults with Obesity

RXRXRecursion2025-12-01 13:30 EST

Recursion Announces Webinar For Upcoming Clinical Data Readout on the TUPELO Phase 1b/2 Trial of REC-4881 in Familial Adenomatous Polyposis on December 8, 2025

STTKShattuck Labs2026-06-05 20:05 EST

Shattuck Labs to Host Investor Call and Webcast on Phase 1 Clinical Data of SL-325, a Potentially First-in-Class DR3 Blocking Antibody, and Pipeline Update on June 8

APGEApogee Therapeutics2026-05-26 20:01 EST

Apogee Therapeutics to Host Conference Call to Report Part B 16-Week Data from the Phase 2 APEX Trial of Zumilokibart in Patients with Moderate-to-Severe Atopic Dermatitis on May 27, 2026

APGEApogee Therapeutics2026-03-22 23:51 EST

Apogee Therapeutics to Host Conference Call to Report Part A 52-Week Data from the Phase 2 APEX Trial of Zumilokibart (APG777) in Patients with Moderate-to-Severe Atopic Dermatitis on March 23, 2026

ENTXEntera Bio2025-08-28 12:00 EST

Entera Bio to Unveil Clinical and Non-Clinical Data Across 3 Oral Peptide Programs at Upcoming September Conferences

IBIOIbio Inc2026-08-04 11:00 EST

iBio Strengthens Clinical Leadership with Appointment of Endocrinologist Molly Carr as Chief Medical Officer

AZNAstraZeneca PLC2016-08-09 06:00 EST

ASTRAZENECA UPDATE ON SELUMETINIB PHASE III TRIAL

AZNAstraZeneca PLC2016-10-26 06:00 EST

Positive results in AstraZeneca Lynparza trial

ENTXEntera Bio2026-08-04 12:30 EST

Entera Bio Phase 2 Data Supporting EB613’s (Oral PTH(1-34)) Anabolic Effect on Postmenopausal Women with Osteoporosis at High Risk for Fracture Selected for Plenary Poster Session Presentation at the ASBMR 2026 Annual Meeting

View all latest news

Ibio Inc

AI-Enabled Antibody Discovery iBio develops antibodies using computational discovery and engineering platforms designed to improve target selection and molecular properties. IBIO-600 IBIO-600 is a long-acting anti-myostatin antibody intended to preserve lean mass and improve body composition during obesity treatment. Cardiopulmonary...

Recent company news

IBIOIbio Inc2026-08-04 11:00 EST

iBio Strengthens Clinical Leadership with Appointment of Endocrinologist Molly Carr as Chief Medical Officer

IBIOIbio Inc2026-07-01 11:00 EST

iBio Reports Single Dose of IBIO-610 Achieved Near-Complete Active Activin E Inhibition Through Eight Weeks in Obese NHP Study

IBIOIbio Inc2026-06-02 20:01 EST

iBio to Participate in Upcoming Healthcare Investor Conferences

IBIOIbio Inc2026-06-02 11:00 EST

iBio Becomes a Clinical-Stage Company with First Participant Dosed in Phase 1 Clinical Trial of IBIO-600 in Adults with Obesity

IBIOIbio Inc2026-05-12 20:05 EST

iBio Reports Q3 Fiscal Year 2026 Financial Results and Provides Corporate Update

Stock data

Close
1.39 USD
Market cap
87.43M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States